Global Health Ventures Inc.
OTC Bulletin Board : GHLV

Global Health Ventures Inc.

November 15, 2010 09:26 ET

Global Health Ventures Files an Application With European Medicines Agency (EMA) for Approval of X-Excite

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 15, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company") is pleased to announce that it has reached a critical milestone in the development of its lead male sexual enhancement drug, X-Excite. The Company has now filed its application for approval with the European regulatory agency to carry out the initial phase of bioequivalent study in man. The current study is expected to take 3-4 months. This is a major stepping stone for the company's lead product X-Excite. After the completion of these trials, the Company will be in a strong position to enter into partnership with major pharmaceutical companies. X-Excite is a sublingual formulation of sildenafil citrate which is marketed under the trade mark Viagra® by Pfizer Inc. Our formulation is substantially different to the current formulation in the market. X-Excite works rapidly with limited side effects as it bypasses liver and gastric metabolic pathways. Pfizer reported sales of $1.9 billion for Viagra® in 2009. The sublingual market for X-Excite is estimated also to be substantial.

The Company's sublingual formulation is designed to enhance drugs to be delivered to the body rapidly and efficiently. This design enables the vast majority of pharmaceutical drugs to be rapidly absorbed through the mucosal membrane of the mouth. This technology works well for drugs that need faster results or have side effects associated with gastrointestinal and/or liver break down. It is scientifically accepted that sublingual drug delivery route is the fastest and most efficient way of drug delivery after direct injection.

"We have now filed an application with the European Regulatory Authorities for approval of X-Excite. The approval process shall take 30 to 60 days. Once we get approval, we will then initiate human clinical trials. We already have a lot of interest from a number of pharmaceutical companies. After the completion of this human clinical trial, the Company will enter into partnership with one or several of these major pharmaceutical companies for further clinical trials and eventually marketing," said Dr. Hassan Salari, Global Health President & CEO.

About Global Health Ventures

Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Contact Information